Elicera Therapeutics AB (publ) (STO:ELIC)

Market Cap	178.19M -39.6%
Revenue (ttm)	7.79M +29.5%
Net Income	-17.98M
EPS	-0.36
Shares Out	66.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	125,228
Open	2.690
Previous Close	2.655
Day's Range	2.630 - 2.735
52-Week Range	2.245 - 7.000
Beta	0.21
Analysts	n/a
Price Target	7.25 (+171.54%)
Earnings Date	Nov 27, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ELIC

Financial Performance

In 2025, Elicera Therapeutics AB's revenue was 10.86 million, an increase of 52.28% compared to the previous year's 7.13 million. Losses were -17.41 million, 8.05% more than in 2024.

Analyst Summary

The average 12-month stock price target for ELIC is kr 7.25, which is an increase of 171.54% from the latest price.

Price Target

kr 7.25

(171.54% upside)

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 2, 2026

Data Sources Report a data error